Shemesh Shay's Form 4 filing
Nuvectis Pharma, Inc. (NVCT) · filed May 18, 2022
- Accession no.
- 0001104659-22-062271
- Filed
- May 18, 2022
- Trade date
- May 16-17, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $4.70K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shemesh ShayCIK 0001896056 | Officer (Chief Dev. & Ops. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2022 | Common Stock | PPurchaseAcquired | +100 | $19.28 | +$1,928 | 1,240,993 | Direct | |
| May 17, 2022 | Common Stock | PPurchaseAcquired | +142 | $19.55F2 | +$2,776.1 | 1,241,135 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects the weighted average purchase price. The range of prices for the shares purchased was $19.23 to $19.94. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.